Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cardiff Oncology, Inc. (DE:XE7C)
FRANKFURT:XE7C
Cardiff Oncology (XE7C) Stock Price & Analysis
2 Followers
XE7C Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.87 - €5.59
Previous Close€4.05
Volume1.50K
Average Volume (3M)811.00
Market Cap
€183.86M
Enterprise Value€115.41M
Total Cash (Recent Filing)$74.82M
Total Debt (Recent Filing)$2.15M
Price to Earnings (P/E)N/A
Beta0.53
Next Earnings
May 02, 2024EPS Estimate
-€0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding44,677,169
10 Day Avg. Volume83
30 Day Avg. Volume811
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.93
Price to Sales (P/S)383.14
Price to Cash Flow (P/CF)-7.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue236.49
Enterprise Value/Gross Profit236.49
Enterprise Value/Ebitda-2.75
Forecast
1Y Price Target
€9.89Price Target Upside144.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Cardiff Oncology News
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.05% Other Institutional Investors
99.95% Public Companies and
Individual Investors
XE7C FAQ
What was Cardiff Oncology, Inc.’s price range in the past 12 months?
Cardiff Oncology, Inc. lowest stock price was €0.87 and its highest was €5.59 in the past 12 months.
What is Cardiff Oncology, Inc.’s market cap?
Currently, no data Available
When is Cardiff Oncology, Inc.’s upcoming earnings report date?
Cardiff Oncology, Inc.’s upcoming earnings report date is May 02, 2024 which is in 7 days.
How were Cardiff Oncology, Inc.’s earnings last quarter?
Cardiff Oncology, Inc. released its earnings results on Feb 29, 2024. The company reported -€0.198 earnings per share for the quarter, beating the consensus estimate of -€0.251 by €0.054.
Is Cardiff Oncology, Inc. overvalued?
According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued.
Does Cardiff Oncology, Inc. pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
What is Cardiff Oncology, Inc.’s EPS estimate?
Cardiff Oncology, Inc.’s EPS estimate is -€0.23.
How many shares outstanding does Cardiff Oncology, Inc. have?
Currently, no data Available
What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?
Cardiff Oncology, Inc. reported an EPS of -€0.198 in its last earnings report, beating expectations of -€0.251. Following the earnings report the stock price went up 23.171%.
Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?
Among the largest hedge funds holding Cardiff Oncology, Inc.’s share is Elkhorn Partners Limited Partnership. It holds Cardiff Oncology, Inc.’s shares valued at 97K.
---
Cardiff Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€9.89 (144.15% Upside)
€9.89 (144.15% Upside)
Blogger Sentiment
Bullish
DE:XE7C Sentiment 100%
Sector Average 69%
Sector Average 69%
Technicals
SMA
Positive
20 days / 200 days
Momentum
198.01%
12-Months-Change
Fundamentals
Return on Equity
-47.07%
Trailing 12-Months
Asset Growth
-29.74%
Trailing 12-Months
Company Description
Cardiff Oncology, Inc.
Trovagene, Inc. is a clinical-stage, precision cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.
---
XE7C Company Deck
---
XE7C Earnings Call
Q4 2024
0:00 / 0:00
---
XE7C Stock 12 Months Forecast
Average Price Target
€9.89
▲(144.15% Upside)
Technical Analysis
Best Analysts Covering XE7C
1 Year
1 Year Success Rate
7/9 ratings generated profit
1 Year Average Return
+87.46%
reiterated a buy rating 2 months ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +87.46% per trade.
---